Why the study?
The study was conducted to evaluate the efficacy and safety of a novel low-dose combination of telmisartan 20 mg and S-amlodipine 1.25 mg in patients with mild-to-moderate hypertension.
Does a low-dose combination of telmisartan and S-amlodipine improve blood pressure reduction compared to monotherapies in patients with mild-to-moderate hypertension?
Population
576 patients with mild-to-moderate uncontrolled hypertension
Comparison
Telmisartan/S-amlodipine 20/1.25 mg vs amlodipine 5 mg, telmisartan 20 mg, or S-amlodipine 1.25 mg
Design
Integrated analysis of two randomized, double-blind, multicenter phase III trials
Follow-up
8 weeks
Key result
Low-dose telmisartan/S-amlodipine (20/1.25 mg) achieved superior reduction in mean sitting systolic blood pressure compared to amlodipine 5 mg (-17.57 vs -13.90 mmHg; p<0.05).
Authors
Loading...
Supports low-dose telmisartan/S-amlodipine initiation in mild-moderate hypertension; extends RCT evidence for fixed-dose ARB/CCB combinations.
RCT (n=576)
double-blind
randomized
Yes
Does a low-dose combination of telmisartan and S-amlodipine improve blood pressure reduction compared to monotherapies in patients with mild-to-moderate hypertension?
Absolute Event Rate: -17.57% vs -13.9%
p-value: p=<0.05
A low-dose combination of telmisartan 20 mg and S-amlodipine 1.25 mg provides superior blood pressure reduction compared to standard monotherapies in patients with mild-to-moderate hypertension.
Na et al. (2026) conducted an RCT in mild-to-moderate hypertension (n=576). telmisartan/S-amlodipine vs. amlodipine 5 mg, telmisartan 20 mg, or S-amlodipine 1.25 mg was evaluated on change in mean sitting systolic blood pressure (msSBP) from baseline to week 8 (p=<0.05). Low-dose telmisartan/S-amlodipine (20/1.25 mg) achieved superior reduction in mean sitting systolic blood pressure compared to amlodipine 5 mg (-17.57 vs -13.90 mmHg; p<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: